BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    GEM PREMIER CHEMSTAT PAK

    MDR report key: 21590088 · Received March 12, 2025

    Report

    Report Number
    1217183-2025-00008
    Event Type
    Malfunction
    Date Received
    March 12, 2025
    Date of Event
    February 11, 2024
    Report Date
    March 12, 2025
    Manufacturer
    INSTRUMENTATION LABORATORY CO.
    Product Code
    JFY
    UDI-DI
    08426951070800
    PMA / PMN Number
    K223090
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    UK
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    AT THE TIME OF THE REPORTED COMPLAINT, INSTRUMENTATION LABORATORY CO. CONDUCTED A COMPREHENSIVE INVESTIGATION, INCLUDING A REVIEW OF THE DATA FROM THE GEM PREMIER CHEMSTAT PAK (CARTRIDGE) IN QUESTION. THE REVIEW IDENTIFIED THE SAMPLE RESULT FOR THE PATIENT ON PARACETAMOL (SAMPLE# 46 ON (B)(6) 2024 @ 16:12). HOWEVER, THE SAMPLE IMMEDIATELY PRIOR IT ALSO REPORTED ELEVATED CREATININE SAMPLE # 46 (SAMPLE # 45 ON (B)(6) 2024 @ 15:48), AND THE ROOT CAUSE OF THE HIGH CREATININE RESULTS COULD NOT BE CONCLUSIVELY DETERMINED. IN ADDITION, DURING VERIFICATION TESTING, NO INTERFERENCE WAS OBSERVED WHEN INTERFERENCE TESTING WAS PERFORMED WITH ACETAMINOPHEN WHICH IS ALSO APPLICABLE TO PARACETAMOL. AS A RESULT, THE COMPLAINT WAS CLOSED, AND NO REMEDIAL ACTION WAS DEEMED NECESSARY IMPORTANT NOTE: INSTRUMENTATION LABORATORY CO. RECENTLY CONDUCTED A SELF-ASSESSMENT OF ITS QUALITY MANAGEMENT SYSTEM AS PART OF ITS ONGOING COMPLIANCE AND QUALITY PROGRAM DUE DILIGENCE. ONE ASPECT OF THIS ASSESSMENT WAS TO PERFORM A RETROSPECTIVE REVIEW OF PRODUCT COMPLAINTS RECEIVED OVER THE PAST TWO YEARS, TO ASSESS IF ANY COMPLAINTS SHOULD HAVE BEEN REPORTED TO FDA FOLLOWING THE FDA GUIDANCE, "MEDICAL DEVICE REPORTING FOR MANUFACTURERS". AS PART OF THIS ASSESSMENT, WE IDENTIFIED A SMALL NUMBER OF COMPLAINTS THAT REQUIRE RETROSPECTIVE REPORTING. PLEASE BE ASSURED THAT INSTRUMENTATION LABORATORY TAKES ITS REGULATORY RESPONSIBILITIES TO THE FDA AND ITS CUSTOMERS SERIOUSLY AND STRIVES TO PRODUCE ONLY THE HIGHEST QUALITY DEVICES. THE NUMBER OF LATE REPORTED COMPLAINTS IS LESS THAN (B)(4) OF THE ANNUAL COMPLAINT VOLUME RECEIVED AND A CAPA HAS BEEN INITIATED TO MITIGATE FUTURE OCCURRENCES. FURTHERMORE, THE COMPANY HAS AND WILL CONTINUE TO DEDICATE THE NECESSARY FINANCIAL AND PERSONNEL RESOURCES (AND MANAGEMENT OVERSIGHT) TO COMPLETE THESE ACTION PLANS IN A TIMELY MANNER.

    Description of Event or Problem · 0

    A CUSTOMER REPORTED THAT CREATININE RESULTS FROM A GEM PREMIER CHEMSTAT PAK (CARTRIDGE) WERE READING HIGH WHEN COMPARED TO THE LABORATORY METHOD (ABBOT ALINITY CREATININE ENZYMATIC ASSAY) AFTER RUNNING A SAMPLE FROM A PATIENT ON PARACETAMOL. NO PATIENT IMPACT WAS REPORTED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1689924 GEM PREMIER CHEMSTAT PAK ENZYMATIC METHOD, CREATININE JFY INSTRUMENTATION LABORATORY CO. 231128B 08426951070800

    Patients

    Seq Age Sex Outcome Treatment
    1 NA Unknown